Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Significant Increase in Short Interest

Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 424,500 shares, an increase of 20.5% from the March 15th total of 352,300 shares. Based on an average trading volume of 137,600 shares, the short-interest ratio is presently 3.1 days. Currently, 0.7% of the shares of the company are sold short.

Nautilus Biotechnology Trading Down 3.5 %

NAUT traded down $0.02 on Friday, reaching $0.69. The stock had a trading volume of 272,183 shares, compared to its average volume of 107,693. The business's 50-day moving average price is $1.02 and its two-hundred day moving average price is $1.76. The company has a market cap of $86.84 million, a P/E ratio of -1.23 and a beta of 1.39. Nautilus Biotechnology has a 12-month low of $0.66 and a 12-month high of $3.09.

Insider Buying and Selling at Nautilus Biotechnology

In related news, CEO Sujal M. Patel acquired 53,300 shares of the firm's stock in a transaction dated Wednesday, March 19th. The stock was acquired at an average price of $0.99 per share, with a total value of $52,767.00. Following the acquisition, the chief executive officer now directly owns 10,117,788 shares in the company, valued at $10,016,610.12. This represents a 0.53 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 40.50% of the company's stock.

Hedge Funds Weigh In On Nautilus Biotechnology

Several institutional investors and hedge funds have recently modified their holdings of the business. SG Americas Securities LLC boosted its position in Nautilus Biotechnology by 56.3% during the fourth quarter. SG Americas Securities LLC now owns 27,483 shares of the company's stock worth $46,000 after purchasing an additional 9,904 shares in the last quarter. Barclays PLC lifted its position in shares of Nautilus Biotechnology by 79.6% during the 3rd quarter. Barclays PLC now owns 106,174 shares of the company's stock valued at $303,000 after buying an additional 47,059 shares in the last quarter. Virtu Financial LLC acquired a new stake in Nautilus Biotechnology in the 4th quarter valued at $28,000. Palumbo Wealth Management LLC increased its holdings in Nautilus Biotechnology by 45.4% in the 4th quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company's stock worth $48,000 after acquiring an additional 8,888 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in Nautilus Biotechnology during the fourth quarter worth $34,000. Hedge funds and other institutional investors own 50.71% of the company's stock.

Analysts Set New Price Targets

Separately, Guggenheim set a $2.50 price target on Nautilus Biotechnology in a report on Friday, February 28th.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.